𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Final adult height in children with Prader–Willi syndrome with and without human growth hormone treatment

✍ Scribed by Moris A. Angulo; Mariano Castro-Magana; Michele Lamerson; Raul Arguello; Siham Accacha; Asjad Khan

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
139 KB
Volume
143A
Category
Article
ISSN
1552-4825

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Growth hormone therapy and scoliosis in
Growth hormone therapy and scoliosis in patients with Prader–Willi syndrome
✍ T. Nagai; K. Obata; T. Ogata; N. Murakami; Y. Katada; A. Yoshino; S. Sakazume; Y 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 1 views

## Abstract Growth hormone (GH) therapy for short stature in patients with Prader–Willi syndrome (PWS) has started worldwide, and various favorable effects have been reported. However, the possibility of progression of scoliosis arises as a new problem of the GH therapy. In this study, we analyzed

Body fat excess and stimulated growth ho
Body fat excess and stimulated growth hormone levels in adult patients with Prader–Willi syndrome
✍ Graziano Grugni; Antonino Crinò; Paride Bertocco; Paolo Marzullo 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

## Abstract It has been suggested that reduced GH secretion in Prader–Willi syndrome (PWS) may simply reflect their excessive fat body mass. However, the GH response to standard provocative tests is significantly lower in PWS adults than obese controls with similar body mass index (BMI). Neverthele

Human growth hormone treatment in prepub
Human growth hormone treatment in prepubertal children with achondroplasia
✍ Weber, Giovanna; Prinster, Chiara; Meneghel, Marta; Russo, Fiorella; Mora, Stefa 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 22 KB 👁 2 views

We studied the effects of recombinant human growth hormone (GH) treatment in 6 prepubertal children with achondroplasia. The patients' age ranged from 2'!'12 to 85/12 years and the GH dose was of 0.1 IU/kg/ day subcutaneously. Auxological assessments and bone age determinations were performed 6 mont